Jer-Yung Chen

Mr. Jer-Yung Chen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in Life
Verified
Journal Article
Open access
PDF file
JCJer-Yung Chen
Jer-Yung Chen
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
RLRu-Ping Lee
Ru-Ping Lee
TYTing-Kuo Yao
Ting-Kuo Yao
CPCheng-Huan Peng
Cheng-Huan Peng
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Post-traumatic osteoarthritis (PTOA) is a distinct form of knee osteoarthritis characterized by accelerated joint degeneration following injury. It poses unique challenges in post-menopausal women due to hormonal changes and altered bone metabolism that create complex pathophysiological environments. This retrospective cohort study compared the effectiveness of different anti-osteoporotic medications in preventing total knee replacement (TKR) in 6155 postmenopausal women with PTOA treated between 2011 and 2021. We compared raloxifene and denosumab, with alendronate serving as the reference group. The primary outcome was TKR occurrence. Cox proportional hazards regression and inverse probability of treatment weighting (IPTW) were performed to estimate hazard ratios, with Kaplan–Meier survival analysis for time-to-event assessment. Participants’ mean (SD) age was 69.4 (10.0) years. Given the retrospective nature and typical delayed presentation of PTOA symptoms, cohort entry was defined as the concurrent diagnosis of PTOA and osteoporosis requiring anti-resorptive therapy. Over a mean follow-up of 5.47 years, 26 patients (0.42%) underwent TKR. Raloxifene was associated with a significantly reduced TKR risk compared to alendronate (IPTW-HR 0.81, 95% CI 0.67–0.99, p = 0.040), representing a 19% relative risk reduction. Kaplan–Meier analysis demonstrated raloxifene maintained the lowest cumulative TKR incidence compared to alendronate and denosumab over time, particularly beyond 5 years. These findings suggest that raloxifene may offer superior joint protection compared with alendronate and denosumab in postmenopausal women with PTOA, supporting its potential as a disease-modifying therapeutic option for this vulnerable population.

28 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
JCJer-Yung Chen
Jer-Yung Chen
STShih-Hung Tsai
Shih-Hung Tsai
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
CPCheng-Huan Peng
Cheng-Huan Peng
TYTing-Kuo Yao
Ting-Kuo Yao
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Background: Romosozumab and teriparatide are approved osteoanabolic therapies for osteoporosis, but direct real-world comparisons remain limited. In this study, we evaluated comparative effectiveness and selected safety outcomes. Methods: Female patients with osteoporosis aged ≥ 50 years who initiated romosozumab or teriparatide were identified in the TriNetX Global Network from January 2020 through December 2025. Outcomes included any osteoporotic fracture, spine or hip fracture, major adverse cardiovascular events (MACE; a nonfatal composite of acute myocardial infarction and stroke), and all-cause mortality, which was analyzed separately. Propensity score matching balanced measured baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression. Results: After 1:1 propensity score matching, each matched cohort included 8616 patients, with follow-up administratively limited to 3 years. Romosozumab initiation was associated with lower risks of any osteoporotic fracture (445 vs. 832 events; HR, 0.68; 95% CI, 0.61–0.77) and spine or hip fracture (341 vs. 682 events; HR, 0.63; 95% CI, 0.55–0.72). The primary analysis also showed a lower estimated risk of MACE (145 vs. 255 events; HR, 0.80; 95% CI, 0.65–0.98), but this association was not consistent across sensitivity analyses. All-cause mortality did not differ significantly (81 vs. 126 events; HR, 0.96; 95% CI, 0.72–1.27). Conclusions: Romosozumab initiation was associated with lower fracture incidence than teriparatide initiation. The cardiovascular and mortality findings do not establish superiority, equivalence, or cardioprotection and should be interpreted cautiously.